New effects of theophylline in patients with chronic obstructive pulmonary disease

Anti-inflammatory action and its underlying mechanism

Mikako Goda, Tsunahiko Hirano, Koji Fukui, Toshiyuki Yamagata, Yuko Yamagata, Masanori Nakanishi, Kazuhito Ueshima, Kazuto Matsunaga, Yoshiaki Minakata, Masakazu Ichinose

Research output: Contribution to journalArticle

Abstract

Oxidative and nitrosative stress and the activation of inflammatory cells including neutrophils are considered to have important roles in the pathogenesis of chronic obstructive pulmonary disease (COPD). This study was designed to examine the effects of oral theophylline in patients with COPD. In a randomized crossover trial, we studied 16 patients with stable stage II or III COPD who gave informed consent. Their mean age was 71±2 years (range, 55 to 80). Their mean pack-year history of cigarette smoking was 68.0±8.0. Patients were randomly assigned to receive theophylline (400 mg/day) for 4 weeks or fluticasone propionate (400 μg/day) for 4 weeks. The other drug was then given for 4 weeks after 4 weeks washout period. The mean (±SD) serum theophylline concentration was 6.32±0.94 μg/mL. Lung function was not significantly altered by treatment with theophylline. During theophylline treatment, the mean total number of cells in induced sputum samples decreased significantly from 2.74± 0.28 to 2.12±0.33 (× 10 6/mL). The mean number of neutrophils fell significantly from 1.97±0.18 to 1.38±0.19 (× 106/mL). The mean concentration of interleukin-8 in the supernatant of induced sputum samples decreased significantly from 3.00±0.68 to 1.72±0.39 ng/mL. The mean number of 3-nitrotyrosine positive cells fell significantly from 1.63±0.28 to 1.10±0.29 (× 106/mL). We conclude that theophylline inhibits airway neutrophil infiltration in patients with COPD. The underlying mechanism may involve the suppression of interleukin-8 production. Theophylline may also inhibit nitrosative stress in the airway of patients with COPD.

Original languageEnglish
Pages (from-to)8-13
Number of pages6
JournalJournal of the Wakayama Medical Society
Volume57
Issue number1
Publication statusPublished - 2006 Mar
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

New effects of theophylline in patients with chronic obstructive pulmonary disease : Anti-inflammatory action and its underlying mechanism. / Goda, Mikako; Hirano, Tsunahiko; Fukui, Koji; Yamagata, Toshiyuki; Yamagata, Yuko; Nakanishi, Masanori; Ueshima, Kazuhito; Matsunaga, Kazuto; Minakata, Yoshiaki; Ichinose, Masakazu.

In: Journal of the Wakayama Medical Society, Vol. 57, No. 1, 03.2006, p. 8-13.

Research output: Contribution to journalArticle

Goda, M, Hirano, T, Fukui, K, Yamagata, T, Yamagata, Y, Nakanishi, M, Ueshima, K, Matsunaga, K, Minakata, Y & Ichinose, M 2006, 'New effects of theophylline in patients with chronic obstructive pulmonary disease: Anti-inflammatory action and its underlying mechanism', Journal of the Wakayama Medical Society, vol. 57, no. 1, pp. 8-13.
Goda, Mikako ; Hirano, Tsunahiko ; Fukui, Koji ; Yamagata, Toshiyuki ; Yamagata, Yuko ; Nakanishi, Masanori ; Ueshima, Kazuhito ; Matsunaga, Kazuto ; Minakata, Yoshiaki ; Ichinose, Masakazu. / New effects of theophylline in patients with chronic obstructive pulmonary disease : Anti-inflammatory action and its underlying mechanism. In: Journal of the Wakayama Medical Society. 2006 ; Vol. 57, No. 1. pp. 8-13.
@article{f58544c9c8764e189508cb360df68d4d,
title = "New effects of theophylline in patients with chronic obstructive pulmonary disease: Anti-inflammatory action and its underlying mechanism",
abstract = "Oxidative and nitrosative stress and the activation of inflammatory cells including neutrophils are considered to have important roles in the pathogenesis of chronic obstructive pulmonary disease (COPD). This study was designed to examine the effects of oral theophylline in patients with COPD. In a randomized crossover trial, we studied 16 patients with stable stage II or III COPD who gave informed consent. Their mean age was 71±2 years (range, 55 to 80). Their mean pack-year history of cigarette smoking was 68.0±8.0. Patients were randomly assigned to receive theophylline (400 mg/day) for 4 weeks or fluticasone propionate (400 μg/day) for 4 weeks. The other drug was then given for 4 weeks after 4 weeks washout period. The mean (±SD) serum theophylline concentration was 6.32±0.94 μg/mL. Lung function was not significantly altered by treatment with theophylline. During theophylline treatment, the mean total number of cells in induced sputum samples decreased significantly from 2.74± 0.28 to 2.12±0.33 (× 10 6/mL). The mean number of neutrophils fell significantly from 1.97±0.18 to 1.38±0.19 (× 106/mL). The mean concentration of interleukin-8 in the supernatant of induced sputum samples decreased significantly from 3.00±0.68 to 1.72±0.39 ng/mL. The mean number of 3-nitrotyrosine positive cells fell significantly from 1.63±0.28 to 1.10±0.29 (× 106/mL). We conclude that theophylline inhibits airway neutrophil infiltration in patients with COPD. The underlying mechanism may involve the suppression of interleukin-8 production. Theophylline may also inhibit nitrosative stress in the airway of patients with COPD.",
author = "Mikako Goda and Tsunahiko Hirano and Koji Fukui and Toshiyuki Yamagata and Yuko Yamagata and Masanori Nakanishi and Kazuhito Ueshima and Kazuto Matsunaga and Yoshiaki Minakata and Masakazu Ichinose",
year = "2006",
month = "3",
language = "English",
volume = "57",
pages = "8--13",
journal = "Journal of the Wakayama Medical Society",
issn = "0043-0013",
publisher = "Wakayama Medical Society",
number = "1",

}

TY - JOUR

T1 - New effects of theophylline in patients with chronic obstructive pulmonary disease

T2 - Anti-inflammatory action and its underlying mechanism

AU - Goda, Mikako

AU - Hirano, Tsunahiko

AU - Fukui, Koji

AU - Yamagata, Toshiyuki

AU - Yamagata, Yuko

AU - Nakanishi, Masanori

AU - Ueshima, Kazuhito

AU - Matsunaga, Kazuto

AU - Minakata, Yoshiaki

AU - Ichinose, Masakazu

PY - 2006/3

Y1 - 2006/3

N2 - Oxidative and nitrosative stress and the activation of inflammatory cells including neutrophils are considered to have important roles in the pathogenesis of chronic obstructive pulmonary disease (COPD). This study was designed to examine the effects of oral theophylline in patients with COPD. In a randomized crossover trial, we studied 16 patients with stable stage II or III COPD who gave informed consent. Their mean age was 71±2 years (range, 55 to 80). Their mean pack-year history of cigarette smoking was 68.0±8.0. Patients were randomly assigned to receive theophylline (400 mg/day) for 4 weeks or fluticasone propionate (400 μg/day) for 4 weeks. The other drug was then given for 4 weeks after 4 weeks washout period. The mean (±SD) serum theophylline concentration was 6.32±0.94 μg/mL. Lung function was not significantly altered by treatment with theophylline. During theophylline treatment, the mean total number of cells in induced sputum samples decreased significantly from 2.74± 0.28 to 2.12±0.33 (× 10 6/mL). The mean number of neutrophils fell significantly from 1.97±0.18 to 1.38±0.19 (× 106/mL). The mean concentration of interleukin-8 in the supernatant of induced sputum samples decreased significantly from 3.00±0.68 to 1.72±0.39 ng/mL. The mean number of 3-nitrotyrosine positive cells fell significantly from 1.63±0.28 to 1.10±0.29 (× 106/mL). We conclude that theophylline inhibits airway neutrophil infiltration in patients with COPD. The underlying mechanism may involve the suppression of interleukin-8 production. Theophylline may also inhibit nitrosative stress in the airway of patients with COPD.

AB - Oxidative and nitrosative stress and the activation of inflammatory cells including neutrophils are considered to have important roles in the pathogenesis of chronic obstructive pulmonary disease (COPD). This study was designed to examine the effects of oral theophylline in patients with COPD. In a randomized crossover trial, we studied 16 patients with stable stage II or III COPD who gave informed consent. Their mean age was 71±2 years (range, 55 to 80). Their mean pack-year history of cigarette smoking was 68.0±8.0. Patients were randomly assigned to receive theophylline (400 mg/day) for 4 weeks or fluticasone propionate (400 μg/day) for 4 weeks. The other drug was then given for 4 weeks after 4 weeks washout period. The mean (±SD) serum theophylline concentration was 6.32±0.94 μg/mL. Lung function was not significantly altered by treatment with theophylline. During theophylline treatment, the mean total number of cells in induced sputum samples decreased significantly from 2.74± 0.28 to 2.12±0.33 (× 10 6/mL). The mean number of neutrophils fell significantly from 1.97±0.18 to 1.38±0.19 (× 106/mL). The mean concentration of interleukin-8 in the supernatant of induced sputum samples decreased significantly from 3.00±0.68 to 1.72±0.39 ng/mL. The mean number of 3-nitrotyrosine positive cells fell significantly from 1.63±0.28 to 1.10±0.29 (× 106/mL). We conclude that theophylline inhibits airway neutrophil infiltration in patients with COPD. The underlying mechanism may involve the suppression of interleukin-8 production. Theophylline may also inhibit nitrosative stress in the airway of patients with COPD.

UR - http://www.scopus.com/inward/record.url?scp=33947611985&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947611985&partnerID=8YFLogxK

M3 - Article

VL - 57

SP - 8

EP - 13

JO - Journal of the Wakayama Medical Society

JF - Journal of the Wakayama Medical Society

SN - 0043-0013

IS - 1

ER -